Modern therapeutic approaches against Pseudomonas aeruginosa infections

Current Medicinal Chemistry

Volumn 22, Issue 14, 2015, Pages 1642-1664

  Dorotkiewicz Jach, Agata ^a   Augustyniak, Daria ^a   Olszak, Tomasz ^a   Drulis Kawa, Zuzanna ^a  

^a UNIVERSITY OF WROC AW   (Poland)

Author keywords

Alternative therapies; Modern therapies; Pseudomonas aeruginosa; Resistance

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL VACCINE; BETA LACTAMASE INHIBITOR; EFFLUX PUMP INHIBITOR; HUMAN MONOCLONAL ANTIBODY; NANOPARTICLE; POLYPEPTIDE ANTIBIOTIC AGENT; QUORUM SENSING INHIBITOR; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOPHAGE; HUMAN; IMMUNE SYSTEM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PSEUDOMONAS INFECTION; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84931275072     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867322666150417122531     Document Type: Article

References (211)

1. Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother., 2009, 64 (Suppl 1), i29-i36.
2. Sader, H.S.; Farrell, D.J.; Flamm, R.K.; Jones, R.N. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn. Microbiol. Infect. Dis., 2014, 78, 443-448.
3. Gales, A.C.; Castanheira, M.; Jones, R.N.; Sader, H.S. Antimicrobial resistance among gram-negative bacilli isolated from Latin America: Results from SENTRY antimicrobial surveillance program (Latin America, 2008-2010). Diagn. Microbiol. Infect. Dis., 2012, 73, 354-360.
4. Jones, R.N.; Flonta, M.; Gurler, N.; Cepparulo, M.; Mendes, R.E.; Castanheira, M. Resistance surveillance program report for selected European Nations (2011). Diagn. Microbiol. Infect. Dis., 2014, 78, 429-436.
5. Dantas, G.; Sommer, M.O.A.; Oluwasegun, R.D.; Church, G.M. Bacteria subsisting on antibiotics. Science, 2008, 320, 100-103.
6. Rice, L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J. Infect. Dis., 2008, 197, 1079-1081.
7. Lambert, P.A. Mechanisms of antibiotic resistance in Pseudomonas Aeruginosa. J. R. Soc. Med., 2002, 95, 22-26.
8. Livermore, D.M. Multiple mechanisms of antimicrobial resistance in Pseudomonas Aeruginosa: Our worst nightmare? Clin. Infect. Dis., 2002, 34, 634-640.
9. Breidenstein, E.B.M.; de la Fuente-Núñez, C.; Hancock, R.E.W. Pseudomonas Aeruginosa: All roads lead to resistance. Trends Microbiol., 2011, 19, 419-426.
10. Farra, A.; Islam, S.; Stralfors, A.; Sorberg, M.; Wretlind, B. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas Aeruginosa to imipenem and meropenem. Int. J. Antimicrob. Agents, 2008, 31, 427-433.
11. Poole, K. Pseudomonas Aeruginosa: Resistance to the max. Front. Microbiol., 2011, 2, 65.
12. Poole, K. Efflux-mediated antimicrobial resistance. J. Antimicrob. Chemother., 2005, 56, 20-51.
13. Zhao, W.-H.; Hu, Z.-Q. Beta-Lactamases identified in clinical isolates of Pseudomonas Aeruginosa. Crit. Rev. Microbiol., 2010, 36, 245-258.
14. Kong, K.F.; Jayawardena, S.R.; Del Puerto, A.; Wiehlmann, L.; Laabs, U.; Tummler, B.; Mathee, K. Characterization of poxB, a chromosomal-encoded pseudomonas aeruginosa oxacillinase. Gene, 2005, 358, 82-92.
15. Ramirez, M.S.; Tolmasky, M.E. Aminoglycoside modifying enzymes. Drug Resist. Updat., 2010, 13, 151-171.
16. Lee, J.K.; Lee, Y.S.; Park, Y.K.; Kim, B.S. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas Aeruginosa. Int. J. Antimicrob. Agents, 2005, 25, 290-295.
17. Zhou, Y.; Yu, H.; Guo, Q.; Xu, X.; Ye, X.; Wu, S.; Guo, Y.; Wang, M. Distribution of 16S rRNA methylases among different species of gram-negative bacilli with high-level resistance to aminoglycosides. Eur. J. Clin. Microbiol. Infect. Dis., 2010, 29, 1349-1353.
18. ECDC. Antimicrobial Resistance Surveillance in Europe 2012. Stockholm, 2012.
19. Kanj, S.S.; Kanafani, Z.A. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extendedspectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas Aeruginosa. Mayo Clin. Proc., 2011, 86, 250-259.
20. Gellatly, S.L.; Hancock, R.E.W. Pseudomonas Aeruginosa: New insights into pathogenesis and host defenses. Pathog. Dis., 2013, 67, 159-173.
21. Cereda, R.F.; Azevedo, H.D.; Girardello, R.; Xavier, D.E.; Gales, A.C. Antimicrobial activity of Ceftobiprole against gram-negative and gram-positive pathogens: Results from INVITA-A-CEFTO brazilian study. Braz. J. Infect. Dis., 2011, 15, 339-348.
22. Walkty, A.; Adam, H.J.; Laverdiere, M.; Karlowsky, J.A.; Hoban, D.J.; Zhanel, G.G. In vitro activity of Ceftobiprole against frequently encountered aerobic and facultative gram-positive and gram-negative bacterial pathogens: Results of the CANWARD 2007-2009 study. Diagn. Microbiol. Infect. Dis., 2011, 69, 348-355.
23. Hong, M.-C.; Hsu, D.I.; Bounthavong, M. Ceftolozane/tazobactam: A novel Antipseudomonal Cephalosporin and B-Lactamaseinhibitor combination. Infect. Drug Resist., 2013, 6, 215-223.
24. Bassetti, M.; Merelli, M.; Temperoni, C.; Astilean, A. New antibiotics for bad bugs: Where are we? Ann. Clin. Microbiol. Antimicrob., 2013, 12, 22.
25. Sugihara, K.; Tateda, K.; Yamamura, N.; Koga, T.; Sugihara, C.; Yamaguchi, K. Efficacy of human-simulated exposures of tomopenem (Formerly CS-023) in a murine model of Pseudomonas Aeruginosa and Methicillin-resistant Staphylococcus Aureus infection. Antimicrob. Agents Chemother., 2011, 55, 5004-5009.
26. Zhanel, G.G.; Lawson, C.D.; Zelenitsky, S.; Findlay, B.; Schweizer, F.; Adam, H.; Walkty, A.; Rubinstein, E.; Gin, A.S.; Hoban, D.J.; Lynch, J.P.; Karlowsky, J.A. Comparison of the nextgeneration aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev. Anti. Infect. Ther., 2012, 10, 459-473.
27. Poulikakos, P.; Falagas, M.E. Aminoglycoside therapy in infectious diseases. Expert Opin. Pharmacother., 2013, 14, 1585-1597.
28. Marra, A.; Bortolon, E.; Molstad, D.; Wu, Y.; Jing, H.; Burak, E. Evaluation of delafloxacin in rat granuloma pouch infections caused by gram-negative pathogens. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, 2011; pp. A1-A680.
29. Quale, J.; Shah, N.; Kelly, P.; Babu, E.; Backer, M.; Rosas-Garcia, G.; Salamera, J.; George, A.; Bratu, S.; Landman, D. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary gram-negative pathogens in New York City. Microb. Drug Resist., 2012, 18, 132-136.
30. Srinivas, N.; Jetter, P.; Ueberbacher, B.J.; Werneburg, M.; Zerbe, K.; Steinmann, J.; Van der Meijden, B.; Bernardini, F.; Lederer, A.; Dias, R.L.; Misson, P.E.; Henze, H.; Zumbrunn, J.; Gombert, F.O.; Obrecht, D.; Hunziker, P.; Schauer, S.; Ziegler, U.; Käch, A.; Eberl, L.; Riedel, K.; DeMarco, S.J.; Robinson, J. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas Aeruginosa. Science, 2010, 327, 1010-1013.
31. Wilbraham, D.; DeMarco, S.; Ograbek, A.; Agren, J.; Wach, A.; Obrecht, D.; Dembowsky, K. Phase I Study with the novel Pseudomonas Aeruginosa antibiotic POL7080 in healthy volunteers. In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27th International Congress of Chemotherapy (ICC), Milan, Italy, 2011.
32. Hernandez, V.; Akama, T.; Alley, M.R.K.; Baker, S.; Mao, W.; Rock, F.; Zhang, Y.K.; Zhang, Y.; Zhou, Y.; Crepin, T.; Cusack, S.; Palencia, A.; Nieman, J.; Anugula, M.; Baek, M.; Diaper, C.; Ha, C.; Keramane, M.; Lu, X.; Mohammad, R.; Savariraj, K.; Sharma, R.; Singh, R.; Subedi, R.; Plattner, J. F1-1637 discovery and mechanism of action of AN3365: A novel boron-containing antibacterial agent in clinical development for gram-negative infections. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, 2010.
33. Freund, Y.R.; Liu, L.; Alley, M.R.K.; Bu, W.; Baker, S.; Lux, S.; Leary, A.O.; Plattner, J.J.; Freund, Y.R. Murine pharmacokinetics and In vivo gram-negative activity of AN3365, a novel boroncontaining protein synthesis inhibitor. neutropenic-mouse thigh model. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, 2010.
34. Zane, L.T.; Shakib, S.; Milne, R.; Liu, L.; Baker, S.; Heerinckx, F.A. Safety, tolerability, and pharmacokinetics of a novel gramnegative antimicrobial, GSK2251052, in healthy subjects. In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27th International Congress of Chemotherapy (ICC), Milan, Italy, 2011.
35. Moir, D.T.; Opperman, T.J.; Butler, M.M.; Bowlin, T.L. New classes of antibiotics. Curr. Opin. Pharmacol., 2012, 12, 535-544.
36. Bax, B.D.; Chan, P.F.; Eggleston, D.S.; Fosberry, A.; Gentry, D.R.; Gorrec, F.; Giordano, I.; Hann, M.M.; Hennessy, A.; Hibbs, M.; Huang, J.; Jones, E.; Jones, J.; Brown, K.K.; Lewis, C.J.; May, E.W.; Saunders, M.R.; Singh, O.; Spitzfaden, C.E.; Shen, C.; Shillings, A.; Theobald, A.J.; Wohlkonig, A.; Pearson, N.D.; Gwynn, M.N. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature, 2010, 466, 935-940.
37. Biondi, S.; Long, S.; Panunzio, M.; L. Qin, W. Current trends in B-lactam based B-lactamases inhibitors. Curr. Med. Chem., 2011, 18, 4223-4236.
38. Ehmann, D.E.; Jahic, H.; Ross, P.L.; Gu, R.-F.; Hu, J.; Durand-Reville, T.F.; Lahiri, S.; Thresher, J.; Livchak, S.; Gao, N.; Palmer, T.; Walkup, G.K.; Fisher, S.L. Kinetics of avibactam inhibition against class A, C, and D B-lactamases. J. Biol. Chem., 2013, 288, 27960-27971.
39. Lagace-Wiens, P.; Walkty, A.; Karlowsky, J. A. Ceftazidime-Avibactam: An evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections. Core Evid., 2014, 9, 13-25.
40. Crandon, J.L.; Schuck, V.J.; Banevicius, M.A.; Beaudoin, M.; Nichols, W.W.; Tanudra, M.A.; Nicolau, D.P.; Kingdom, U. Comparative. In vitro and In vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas Aeruginosa. Antimicrob. Agents Chemother., 2012, 56, 6137-6146.
41. Sader, H.S.; Flamm, R.K.; Jones, R.N. Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. medical centers in 2010-2011. Antimicrob. Agents Chemother., 2013, 57, 1982-1988.
42. Crandon, J.L.; Nicolau, D.P. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-B-lactamase producers. Antimicrob. Agents Chemother., 2013, 57, 3299-3306.
43. Hirsch, E.B.; Ledesma, K.R.; Chang, K.-T.; Schwartz, M.S.; Motyl, M.R.; Tam, V.H. In vitro activity of MK-7655, a novel B-lactamase inhibitor, in combination with imipenem against carbapenem-resistant gram-negative bacteria. Antimicrob. Agents Chemother., 2012, 56, 3753-3757.
44. Livermore, D.M.; Warner, M.; Mushtaq, S. Activity of MK-7655 combined with imipenem against enterobacteriaceae and Pseudomonas Aeruginosa. J. Antimicrob. Chemother., 2013, 68, 2286-2290.
45. Ishii, Y.; Eto, M.; Mano, Y.; Tateda, K.; Yamaguchi, K. In vitro potentiation of carbapenems with ME1071, a novel metallo-Betalactamase inhibitor, against metallo-Beta-lactamase-producing Pseudomonas Aeruginosa clinical isolates. Antimicrob. Agents Chemother., 2010, 54, 3625-3629.
46. Yamada, K.; Yanagihara, K.; Kaku, N.; Harada, Y.; Migiyama, Y.; Nagaoka, K.; Morinaga, Y.; Nakamura, S.; Imamura, Y.; Miyazaki, T.; Izumikawa, K.; Kakeya, H.; Hasegawa, H.; Yasuoka, A.; Kohno, S. In vivo efficacy of biapenem with ME1071, a novel metallo-beta-lactamase (MBL) inhibitor, in a murine model mimicking ventilator-associated Pneumonia caused by MBLproducing Pseudomonas Aeruginosa. Int. J. Antimicrob. Agents, 2013, 42, 238-243.
47. Hurley, M.N.; Camara, M.; Smyth, A.R. Novel approaches to the treatment of Pseudomonas Aeruginosa infections in cystic fibrosis. Eur. Respir. J., 2012, 40, 1014-1023.
48. Renau, T.E.; Leger, R.; Flamme, E.M.; Sangalang, J.; She, M.W.; Yen, R.; Gannon, C.L.; Griffith, D.; Chamberland, S.; Lomovskaya, O.; Hecker, S.J.; Lee, V.J.; Ohta, T.; Nakayama, K. Inhibitors of efflux pumps in Pseudomonas Aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J. Med. Chem., 1999, 42, 4928-4931.
49. Lomovskaya, O.; Warren, M.S.; Lee, A.; Galazzo, J.; Fronko, R.; Lee, M.A.Y.; Blais, J.; Cho, D.; Chamberland, S.; Renau, T.O.M.; Leger, R.; Hecker, S.; Watkins, W.; Hoshino, K.; Ishida, H.; Lee, V.J. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas Aeruginosa: Novel agents for combination therapy. Antimicrob. Agents Chemother., 2001, 45, 105-116.
50. Mao, W.; Warren, M.S.; Lee, A.; Mistry, A.; Lomovskaya, O. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas Aeruginosa. Antimicrob. Agents Chemother., 2001, 45, 2001-2007.
51. Lamers, R.P.; Cavallari, J.F.; Burrows, L.L. The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PA-Beta-N) permeabilizes the outer membrane of gram-negative bacteria. PLoS One, 2013, 8, 1-7.
52. Ji, Y.; Zhang, B.; Van, S.F.; Horn; Warren, P.; Woodnutt, G.; Burnham, M.K.; Rosenberg, M. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science, 2001, 293, 2266-2269.
53. Marquez, B. Bacterial efflux systems and efflux pumps inhibitors. Biochimie, 2005, 87, 1137-1147.
54. Yoshida, K. Ichi; Nakayama, K.; Yokomizo, Y.; Ohtsuka, M.; Takemura, M.; Hoshino, K.; Kanda, H.; Namba, K.; Nitanai, H.; Zhang, J.Z.; Lee, V.J.; Watkins, W.J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas Aeruginosa. Part 6: Exploration of aromatic substituents. Bioorg. Med. Chem., 2006, 14, 8506-8518.
55. Yoshida, K.I.; Nakayama, K.; Kuru, N.; Kobayashi, S.; Ohtsuka, M.; Takemura, M.; Hoshino, K.; Kanda, H.; Zhang, J.Z.; Lee, V.J.; Watkins, W.J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas Aeruginosa. Part 5: carbon-substituted analogues at the C-2 position. Bioorg. Med. Chem., 2006, 14, 1993-2004.
56. Yoshida, K. Ichi.; Nakayama, K.; Ohtsuka, M.; Kuru, N.; Yokomizo, Y.; Sakamoto, A.; Takemura, M.; Hoshino, K.; Kanda, H.; Nitanai, H.; Namba, K.; Yoshida, K.; Imamura, Y.; Zhang, J.Z.; Lee, V.J.; Watkins, W.J. MexAB-OprM specific efflux pump inhibitors in Pseudomonas Aeruginosa. Part 7: Highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg. Med. Chem., 2007, 15, 7087-7097.
57. Hirakata, Y.; Kondo, A.; Hoshino, K.; Yano, H.; Arai, K.; Hirotani, A.; Kunishima, H.; Yamamoto, N.; Hatta, M.; Kitagawa, M.; Kohno, S.; Kaku, M. Efflux pump inhibitors reduce the invasiveness of Pseudomonas Aeruginosa. Int. J. Antimicrob. Agents, 2009, 34, 343-346.
58. Pagès, J.-M.; Masi, M.; Barbe, J. Inhibitors of efflux pumps in gram-negative bacteria. Trends Mol. Med., 2005, 11, 382-389.
59. Page, M.G.; Heim, J. Prospects for the next anti-pseudomonas drug. Curr. Opin. Pharmacol., 2009, 9, 558-565.
60. Wilder, C.N.; Diggle, S.P.; Schuster, M. Cooperation and cheating in Pseudomonas Aeruginosa: The roles of the las, rhl and pqs quorum-sensing systems. ISME J., 2011, 5, 1332-1343.
61. Tay, S.B.; Yew, W.S. Development of quorum-based antivirulence therapeutics targeting gram-negative bacterial pathogens. Int. J. Mol. Sci., 2013, 14, 16570-16599.
62. Gilbert, K.B.; Kim, T.H.; Gupta, R.; Greenberg, E.P.; Schuster, M. Global position analysis of the Pseudomonas Aeruginosa quorumsensing transcription factor LasR. Mol. Microbiol., 2009, 73, 1072-1085.
63. Dubern, J.-F.; Diggle, S.P. Quorum Sensing by 2-alkyl-4-quinolones in Pseudomonas Aeruginosa and other bacterial species. Mol. Biosyst., 2008, 4, 882-888.
64. Chugani, S.A.; Whiteley, M.; Lee, K.M.; D'Argenio, D.; Manoil, C.; Greenberg, E.P. QscR, a modulator of quorum-sensing signal synthesis and virulence in Pseudomonas Aeruginosa. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 2752-2757.
65. Schuster, M.; Lostroh, C.P.; Ogi, T.; Greenberg, E.P. Identification, timing, and signal specificity of Pseudomonas Aeruginosa quorumcontrolled genes: A transcriptome analysis. J. Bacteriol., 2003, 185, 2066-2079.
66. Déziel, E.; Gopalan, S.; Tampakaki, A.P.; Lépine, F.; Padfield, K.E.; Saucier, M.; Xiao, G.; Rahme, L.G. The contribution of MvfR to Pseudomonas Aeruginosa pathogenesis and quorum sensing circuitry regulation: Multiple quorum sensing-regulated genes are modulated without affecting lasRI, rhlRI or the production of N-acyl-L-homoserine lactones. Mol. Microbiol., 2005, 55, 998-1014.
67. Lee, D.G.; Urbach, J.M.; Wu, G.; Liberati, N.T.; Feinbaum, R.L.; Miyata, S.; Diggins, L.T.; He, J.; Saucier, M.; Déziel, E.; Friedman, L.; Li, L.; Grills, G.; Montgomery, K.; Kucherlapati, R.; Rahme, L.G.; Ausubel, F.M. Genomic analysis reveals that Pseudomonas Aeruginosa virulence is combinatorial. Genome Biol., 2006, 7, R90.
68. Lequette, Y.; Lee, J.-H.; Ledgham, F.; Lazdunski, A.; Greenberg, E.P. A distinct QscR regulon in the Pseudomonas Aeruginosa quorum-sensing circuit. J. Bacteriol., 2006, 188, 3365-3370.
69. Smith, R.S.; Iglewski, B.H. Pseudomonas Aeruginosa quorum sensing as a potential antimicrobial target. J. Clin. Invest., 2003, 112, 1460-1465.
70. Yang, Y.-X.; Xu, Z.-H.; Zhang, Y.-Q.; Tian, J.; Weng, L.-X.; Wang, L.-H. A new quorum-sensing inhibitor attenuates virulence and decreases antibiotic resistance in Pseudomonas Aeruginosa. J. Microbiol., 2012, 50, 987-993.
71. Calfee, M.W.; Coleman, J.P.; Pesci, E.C. Interference with Pseudomonas quinolone signal synthesis inhibits virulence factor expression by Pseudomonas Aeruginosa. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 11633-11637.
72. Lesic, B.; Lepine, F.; Deziel, E.; Zhang, J.; Zhang, Q.; Padfield, K.; Castonguay, M.H.; Milot, S.; Stachel, S.; Tzika, A.A.; Tompkins, R.G.; Rahme, L.G. Inhibitors of pathogen intercellular signals as selective anti-infective compounds. PLoS Pathog., 2007, 3, 1229-1239.
73. Sarabhai, S.; Sharma, P.; Capalash, N. Ellagic acid derivatives from terminalia chebula retz. Downregulate the expression of quorum sensing genes to attenuate Pseudomonas Aeruginosa PAO1 virulence. PLoS One, 2013, 8, e53441.
74. Passador, L.; Tucker, K.D.; Guertin, K.R.; Journet, M.P.; Kende, A.S.; Iglewski, B.H. Functional analysis of the Pseudomonas Aeruginosa autoinducer PAI. J. Bacteriol., 1996, 178, 5995-6000.
75. Geske, G.D.; O'Neill, J.C.; Miller, D.M.; Mattmann, M.E.; Blackwell, H.E. Modulation of bacterial quorum sensing with synthetic ligands: systematic evaluation of N-acylated homoserine lactones in multiple species and new insights into their mechanisms of action. J. Am. Chem. Soc., 2007, 129, 13613-13625.
76. Morkunas, B.; Galloway, W.R.J.D.; Wright, M.; Ibbeson, B.M.; Hodgkinson, J.T.; O'Connell, K.M.G.; Bartolucci, N.; Della Valle, M.; Welch, M.; Spring, D.R. Inhibition of the production of the Pseudomonas Aeruginosa virulence factor pyocyanin in wild-type cells by quorum sensing autoinducer-mimics. Org. Biomol. Chem., 2012, 10, 8452-8464.
77. Annapoorani, A.; Umamageswaran, V.; Parameswari, R.; Pandian, S.K.; Ravi, A.V. Computational discovery of putative quorum sensing inhibitors against LasR and RhlR receptor proteins of Pseudomonas Aeruginosa. J. Comput. Aided. Mol. Des., 2012, 26, 1067-1077.
78. Hentzer, M.; Wu, H.; Andersen, J.B.; Riedel, K.; Rasmussen, T.B.; Bagge, N.; Kumar, N.; Schembri, M.A.; Song, Z.; Kristoffersen, P.; Manefield, M.; Costerton, J.W.; Molin, S.; Eberl, L.; Steinberg, P.; Kjelleberg, S.; Høiby, N.; Givskov, M. Attenuation of Pseudomonas Aeruginosa virulence by quorum sensing inhibitors. EMBO J., 2003, 22, 3803-3815.
79. Lu, C.; Kirsch, B.; Zimmer, C.; de Jong, J.C.; Henn, C.; Maurer, C.K.; Müsken, M.; Häussler, S.; Steinbach, A.; Hartmann, R.W. Discovery of antagonists of PqsR, a key player in 2-alkyl-4-quinolone-dependent quorum sensing in Pseudomonas Aeruginosa. Chem. Biol., 2012, 19, 381-390.
80. Czajkowski, R.; Jafra, S. Quenching of acyl-homoserine lactonedependent quorum sensing by enzymatic disruption of signal molecules. Acta Biochim. Pol., 2009, 56, 1-16.
81. Lin, Y.-H.; Xu, J.-L.; Hu, J.; Wang, L.-H.; Ong, S.L.; Leadbetter, J.R.; Zhang, L.-H. Acyl-homoserine lactone acylase from ralstonia strain XJ12B represents a novel and potent class of quorumquenching enzymes. Mol. Microbiol., 2003, 47, 849-860.
82. Reimmann, C.; Ginet, N.; Michel, L.; Keel, C.; Michaux, P.; Krishnapillai, V.; Zala, M.; Heurlier, K.; Triandafillu, K.; Harms, H.; Défago, G.; Haas, D. Genetically programmed autoinducer destruction reduces virulence gene expression and swarming motility in Pseudomonas Aeruginosa PAO1. Microbiology, 2002, 148, 923-932.
83. Migiyama, Y.; Kaneko, Y.; Yanagihara, K.; Morohoshi, T.; Morinaga, Y.; Nakamura, S.; Miyazaki, T.; Hasegawa, H.; Izumikawa, K.; Kakeya, H.; Kohrogi, H.; Kohno, S. Efficacy of AiiM, an N-acylhomoserine lactonase, against Pseudomonas Aeruginosa in a mouse model of acute pneumonia. Antimicrob. Agents Chemother., 2013, 57, 3653-3658.
84. Bijtenhoorn, P.; Mayerhofer, H.; Müller-Dieckmann, J.; Utpatel, C.; Schipper, C.; Hornung, C.; Szesny, M.; Grond, S.; Thürmer, A.; Brzuszkiewicz, E.; Daniel, R.; Dierking, K.; Schulenburg, H.; Streit, W.R. A novel metagenomic short-chain dehydrogenase/reductase attenuates Pseudomonas Aeruginosa biofilm formation and virulence on Caenorhabditis Elegans. PLoS One, 2011, 6, e26278.
85. Pustelny, C.; Albers, A.; Büldt-Karentzopoulos, K.; Parschat, K.; Chhabra, S.R.; Càmara, M.; Williams, P.; Fetzner, S. Dioxygenasemediated quenching of quinolone-dependent quorum sensing in Pseudomonas Aeruginosa. Chem. Biol., 2009, 16, 1259-1267.
86. Wahjudi, M.; Papaioannou, E.; Hendrawati, O.; van Assen, A.H.G.; van Merkerk, R.; Cool, R.H.; Poelarends, G.J.; Quax, W.J. PA0305 of Pseudomonas Aeruginosa is a quorum quenching acylhomoserine lactone acylase belonging to the Ntn hydrolase superfamily. Microbiology, 2011, 157, 2042-2055.
87. Sio, C.F.; Otten, L.G.; Cool, R.H.; Diggle, S.P.; Braun, P.G.; Bos, R.; Daykin, M.; Cámara, M.; Williams, P.; Quax, W.J. Quorum quenching by an N-acyl-homoserine lactone acylase from Pseudomonas Aeruginosa PAO1. Infect. Immun., 2006, 74, 1673-1682.
88. De Lamo Marin, S.; Xu, Y.; Meijler, M.M.; Janda, K.D. Antibody catalyzed hydrolysis of a quorum sensing signal found in gramnegative bacteria. Bioorg. Med. Chem. Lett., 2007, 17, 1549-1552.
89. Kaufmann, G.F.; Park, J.; Mee, J.M.; Ulevitch, R.J.; Janda, K.D. The quorum quenching antibody RS2-1G9 protects macrophages from the cytotoxic effects of the Pseudomonas Aeruginosa quorum sensing signalling molecule N-3-oxo-dodecanoyl-homoserine lactone. Mol. Immunol., 2008, 45, 2710-2714.
90. Rasmussen, T.B.; Skindersoe, M.E.; Bjarnsholt, T.; Phipps, R.K.; Christensen, K.B.; Jensen, P.O.; Andersen, J.B.; Koch, B.; Larsen, T.O.; Hentzer, M.; Eberl, L.; Hoiby, N.; Givskov, M. Identity and effects of quorum-sensing inhibitors produced by penicillium species. Microbiology, 2005, 151, 1325-1340.
91. Jakobsen, T.H.; Bragason, S.K.; Phipps, R.K.; Christensen, L.D.; van Gennip, M.; Alhede, M.; Skindersoe, M.; Larsen, T.O.; Hoiby, N.; Bjarnsholt, T.; Givskov, M. Food as a source for quorum sensing inhibitors: Iberin from horseradish revealed as a quorum sensing inhibitor of Pseudomonas Aeruginosa. Appl. Environ. Microbiol., 2012, 78, 2410-2421.
92. Jakobsen, T.H.; van Gennip, M.; Phipps, R.K.; Shanmugham, M.S.; Christensen, L.D.; Alhede, M.; Skindersoe, M.E.; Rasmussen, T.B.; Friedrich, K.; Uthe, F.; Jensen, P.O.; Moser, C.; Nielsen, K.F.; Eberl, L.; Larsen, T.O.; Tanner, D.; Hoiby, N.; Bjarnsholt, T.; Givskov, M. Ajoene, a sulfur-rich molecule from garlic, inhibits genes controlled by quorum sensing. Antimicrob. Agents Chemother., 2012, 56, 2314-2325.
93. Hirakawa, H.; Tomita, H. Interference of bacterial cell-to-cell communication: A new concept of antimicrobial chemotherapy breaks antibiotic resistance. Front. Microbiol., 2013, 4, 114.
94. Pelgrift, R.Y.; Friedman, A.J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev., 2013, 65, 1803-1815.
95. Singh, R.; Smitha, M.S.; Singh, S.P. The role of nanotechnology in combating multi-drug resistant bacteria. J. Nanosci. Nanotechnol., 2014, 14, 4745-4756.
96. Ulrich, A.S. Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep., 2002, 22, 129-150.
97. Krieger, J.; Childs, S.; Klimberg, I. UTI treatment using liposomal amikacin (MiKasome®). In: Ninth European Congress of Clinical Microbiology and Infectious Diseases; Berlin, 1999; p. A194.
98. Drulis-Kawa, Z.; Dorotkiewicz-Jach, A. Liposomes as delivery systems for antibiotics. Int. J. Pharm., 2010, 387, 187-198.
99. DiTizio, V.; Ferguson, G.W.; Mittelman, M.W.; Khoury, A.E.; Bruce, A.W.; Di Cosmo, F. A liposomal hydrogel for the prevention of bacterial adhesion to catheters. Biomaterials, 1998, 19, 1877-1884.
100. Trafny, E.A.; Stepińska, M.; Antos, M.; Grzybowski, J. Effects of free and liposome-encapsulated antibiotics on adherence of Pseudomonas Aeruginosa to collagen Type I. Antimicrob. Agents Chemother., 1995, 39, 2645-2649.
101. Beaulac, C.; Sachetelli, S.; Lagace, J. In-Vitro Bactericidal Efficacy of Sub-MIC Concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J. Antimicrob. Chemother., 1998, 41, 35-41.
102. Sachetelli, S.; Khalil, H.; Chen, T.; Beaulac, C.; Senechal, S.; Lagace, J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta-Biomembr., 2000, 1463, 254-266.
103. Omri, A.; Ravaoarinoro, M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on gram-negative and gram-positive bacteria. Int. J. Antimicrob. Agents, 1996, 7, 9-14.
104. Omri, A.; Ravaoarinoro, M. Comparison of the bactericidal action of amikacin, netilmicin and tobramycin in free and liposomal formulation against Pseudomonas Aeruginosa. Chemotherapy, 1996, 42, 170-176.
105. Ma, Y.; Wang, Z.; Zhao, W.; Lu, T.; Wang, R.; Mei, Q.; Chen, T. Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int. J. Nanomed., 2013, 8, 2351-2360.
106. Halwani, M.; Mugabe, C.; Azghani, A.O.; Lafrenie, R.M.; Kumar, A.; Omri, A. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia Cenocepacia. J. Antimicrob. Chemother., 2007, 60, 760-769.
107. Halwani, M.; Blomme, S.; Suntres, Z.E.; Alipour, M.; Azghani, A.O.; Kumar, A.; Omri, A. Liposomal bismuth-ethanedithiol formulation enhances antimicrobial activity of tobramycin. Int. J. Pharm., 2008, 358, 278-284.
108. Mugabe, C.; Halwani, M.; Azghani, A.O.; Lafrenie, R.M.; Omri, A. Mechanism of enhanced activity of liposome-entrapped aminoglycosides against resistant strains of pseudomonas Aeruginosa. Antimicrob. Agents Chemother., 2006, 50, 2016-2022.
109. Rukholm, G.; Mugabe, C.; Azghani, A.O.; Omri, A. Antibacterial activity of liposomal gentamicin against Pseudomonas Aeruginosa: A time-kill study. Int. J. Antimicrob. Agents, 2006, 27, 247-252.
110. Furneri, P.M.; Fresta, M.; Puglisi, G.; Tempera, G. Ofloxacinloaded liposomes: In vitro activity and drug accumulation in Bacteria. Antimicrob. Agents Chemother., 2000, 44, 2458-2464.
111. Gubernator, J.; Drulis-Kawa, Z.; Dorotkiewicz-Jach, A.; Doroszkiewicz, W.; Kozubek, A. In vitro Antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains. Lett. Drug Des. Discov., 2007, 4, 297.
112. Drulis-Kawa, Z.; Gubernator, J.; Dorotkiewicz-Jach, A.; Doroszkiewicz, W.; Kozubek, A. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas Aeruginosa strains. Int. J. Pharm., 2006, 315, 59-66.
113. Rivera, M.; Bryan, L.E.; Hancock, R.E.; McGroarty, E.J. Heterogeneity of lipopolysaccharides from Pseudomonas Aeruginosa: Analysis of lipopolysaccharide chain length. J. Bacteriol., 1988, 170, 512-521.
114. Poole, K. Outer Membranes and Efflux: The path to multidrug resistance in gram-negative bacteria. Curr. Pharm. Biotechnol., 2002, 3, 77-98.
115. Drulis-Kawa, Z.; Dorotkiewicz-Jach, A.; Gubernator, J.; Gula, G.; Bocer, T.; Doroszkiewicz, W. The interaction between Pseudomonas Aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope Properties of Bacterial Cell. Int. J. Pharm., 2009, 367, 211-219.
116. Alhajlan, M.; Alhariri, M.; Omri, A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas Aeruginosa virulence factors. Antimicrob. Agents Chemother., 2013, 57, 2694-2704.
117. Halwani, M.; Hebert, S.; Suntres, Z.E.; Lafrenie, R.M.; Azghani, A.O.; Omri, A. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas Aeruginosa. Int. J. Pharm., 2009, 373, 141-146.
118. Alhariri, M.; Omri, A. Efficacy of liposomal bismuthethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas Aeruginosa infection. Antimicrob. Agents Chemother., 2013, 57, 569-578.
119. He, J.; Abdelraouf, K.; Ledesma, K.R.; Chow, D.S.-L.; Tam, V.H. Pharmacokinetics and efficacy of liposomal polymyxin B in a murine pneumonia model. Int. J. Antimicrob. Agents, 2013, 42, 559-564.
120. Okusanya, O.O.; Bhavnani, S.M.; Hammel, J.; Minic, P.; Dupont, L.J.; Forrest, A.; Mulder, G.-J.; Mackinson, C.; Ambrose, P.G.; Gupta, R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother., 2009, 53, 3847-3854.
121. Doan, T.V.P.; Couet, W.; Olivier, J.C. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery. Int. J. Pharm., 2011, 414, 112-117.
122. Hadinoto, K.; Cheow, W.S. Nano-antibiotics in chronic lung infection therapy against Pseudomonas Aeruginosa. Coll. Surf. B. Biointerfaces, 2014, 116C, 772-785.
123. Ungaro, F.; D'Angelo, I.; Coletta, C.; D'Emmanuele Di Villa Bianca, R.; Sorrentino, R.; Perfetto, B.; Tufano, M.A.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release, 2012, 157, 149-159.
124. Cheow, W.S.; Chang, M.W.; Hadinoto, K. The roles of lipid in anti-biofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surfaces A Physicochem. Eng. Asp., 2011, 389, 158-165.
125. Abdelghany, S.M.; Quinn, D.J.; Ingram, R.J.; Gilmore, B.F.; Donelly, R.F.; Taggart, C.C.; Scott, C.J. Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas Aeruginosa infection. Int. J. Nanomed., 2012, 7, 4053-4063.
126. Hajipour, M.J.; Fromm, K.M.; Akbar Ashkarran, A.; Jimenez de Aberasturi, D.; Larramendi, I.R. de; Rojo, T.; Serpooshan, V.; Parak, W.J.; Mahmoudi, M. Antibacterial properties of nanoparticles. Trends Biotechnol., 2012, 30, 499-511.
127. Friedman, A.; Blecher, K.; Sanchez, D.; Tuckman-Vernon, C.; Gialanella, P.; Friedman, J.M.; Martinez, L.R.; Nosanchuk, J.D. Susceptibility of gram-positive and-negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence, 2011, 2, 217-221.
128. Friedman, A.J.; Blecher, K.; Schairer, D.; Tuckman-Vernon, C.; Nacharaju, P.; Sanchez, D.; Gialanella, P.; Martinez, L.R.; Friedman, J.M.; Nosanchuk, J.D. Improved antimicrobial efficacy with nitric oxide releasing nanoparticle generated Snitrosoglutathione. Nitric Oxide-Biol. Chem., 2011, 25, 381-386.
129. Lara, H.; Ayala-Núñez, N.; Ixtepan Turrent, L.; Rodríguez Padilla, C. Bactericidal effect of silver nanoparticles against multidrugresistant bacteria. World J. Microbiol. Biotechnol., 2010, 26, 615-621.
130. Blecher, K.; Nasir, A.; Friedman, A. The growing role of nanotechnology in combating infectious disease. Virulence, 2011, 2, 395-401.
131. Huh, A.J.; Kwon, Y.J. "Nanoantibiotics": A new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant Era. J. Control. Release, 2011, 156, 128-145.
132. Luo, Y.; Hossain, M.; Wang, C.; Qiao, Y.; An, J.; Ma, L.; Su, M. Targeted nanoparticles for enhanced X-ray radiation killing of multidrug-resistant bacteria. Nanoscale, 2013, 5, 687-694.
133. Huang, L.; Dai, T.; Xuan, Y.; Tegos, G.P.; Hamblin, M.R. Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: Efficacy against bacterial burn infections. Antimicrob. Agents Chemother., 2011, 55, 3432-3438.
134. Jenssen, H.; Hamill, P.; Hancock, R.E.W. Peptide Antimicrobial Agents. Clin. Microbiol. Rev., 2006, 19, 491-511.
135. Brogden, K. a. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol., 2005, 3, 238-250.
136. Marr, A.K.; Gooderham, W.J.; Hancock, R.E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol., 2006, 6, 468-472.
137. Hancock, R.E.W.; Patrzykat, a. Clinical development of cationic antimicrobial peptides: From natural to novel antibiotics. Curr. Drug Targets. Infect. Disord., 2002, 2, 79-83.
138. Augustyniak, D.; Nowak, J.; Lundy, F.T. Direct and indirect antimicrobial activities of neuropeptides and their therapeutic potential. Curr. Protein Pept. Sci., 2012, 13, 723-738.
139. Lai, L.P.; Mitchell, J. Parathyroid hormone inhibits phosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2 through inhibition of c-Raf and activation of MKP-1 in osteoblastic cells. Cell Biochem. Funct., 2009, 27, 269-275.
140. Zhang, L.; Parente, J.; Harris, S.M.; Woods, D.E.; Hancock, R.E.W.; Falla, T.J. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob. Agents Chemother., 2005, 49, 2921-2927.
141. J. Afacan, N.; T.Y. Yeung, A.; M. Pena, O.; E.W. Hancock, R. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr. Pharm. Des., 2012, 18, 807-819.
142. Malmsten, M.; Kasetty, G.; Pasupuleti, M.; Alenfall, J.; Schmidtchen, A. Highly selective end-tagged antimicrobial peptides derived from PRELP. PLoS One, 2011, 6, e16400.
143. Patch, J. a; Barron, A.E. Mimicry of bioactive peptides via nonnatural, sequence-specific peptidomimetic oligomers. Curr. Opin. Chem. Biol., 2002, 6, 872-877.
144. Kapoor, R.; Wadman, M.W.; Dohm, M.T.; Czyzewski, A.M.; Spormann, A.M.; Barron, A.E. Antimicrobial peptoids are effective against Pseudomonas Aeruginosa biofilms. Antimicrob. Agents Chemother., 2011, 55, 3054-3057.
145. Scott, M.G.; Dullaghan, E.; Mookherjee, N.; Glavas, N.; Waldbrook, M.; Thompson, A.; Wang, A.; Lee, K.; Doria, S.; Hamill, P.; Yu, J.J.; Li, Y.; Donini, O.; Guarna, M.M.; Finlay, B.B.; North, J.R.; Hancock, R.E.W. An anti-Infective peptide that selectively modulates the innate immune response. Nat. Biotechnol., 2007, 25, 465-472.
146. Steinstraesser, L.; Hirsch, T.; Schulte, M.; Kueckelhaus, M.; Jacobsen, F.; Mersch, E. a; Stricker, I.; Afacan, N.; Jenssen, H.; Hancock, R.E.W.; Kindrachuk, J. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS One, 2012, 7, e39373.
147. Giacometti, A.; Cirioni, O.; Schimizzi, A.M.; Del Prete, M.S.; Barchiesi, F.; D'Errico, M.M.; Petrelli, E.; Scalise, G. Epidemiology and microbiology of surgical wound infections. J. Clin. Microbiol., 2000, 38, 918-922.
148. Lang, A.B.; Horn, M.P.; Imboden, M. a; Zuercher, A.W. Prophylaxis and therapy of Pseudomonas Aeruginosa infection in cystic fibrosis and immunocompromised patients. Vaccine, 2004, 22 (Suppl 1), S44-S48.
149. Döring, G.; Pier, G.B. Vaccines and immunotherapy against Pseudomonas Aeruginosa. Vaccine, 2008, 26, 1011-1024.
150. Sharma, A.; Krause, A.; Worgall, S. Recent developments for Pseudomonas vaccines. Hum. Vaccin., 2011, 7, 999-1011.
151. Schaad, U.B.; Lang, A.B.; Wedgwood, J.; Ruedeberg, A.; Que, J.U.; Furer, E.; Cryz, S.J. Safety and immunogenicity of Pseudomonas Aeruginosa conjugate A vaccine in cystic fibrosis. Lancet, 1991, 338, 1236-1237.
152. Döring, G.; Meisner, C.; Stern, M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas Aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl. Acad. Sci. U. S. A., 2007, 104, 11020-11025.
153. Kim, D.K.; Kim, J.J.; Kim, J.H.; Woo, Y.M.; Kim, S.; Yoon, D.W.; Choi, C.S.; Kim, I.; Park, W.J.; Lee, N.; Jung, S.B.; Ahn, B.Y.; Nam, S.W.; Yoon, S.M.; Choi, W.J. Comparison of two immunization schedules for a Pseudomonas Aeruginosa outer membrane proteins vaccine in burn patients. Vaccine, 2000, 19, 1274-1283.
154. Jensen, P.O.; Givskov, M.; Bjarnsholt, T.; Moser, C. The immune system vs. Pseudomonas Aeruginosa biofilms. FEMS Immunol. Med. Microbiol., 2010, 59, 292-305.
155. Nelson, A.L.; Dhimolea, E.; Reichert, J.M. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov., 2010, 9, 767-774.
156. François, B.; Luyt, C.-E.; Dugard, A.; Wolff, M.; Diehl, J.-L.; Jaber, S.; Forel, J.-M.; Garot, D.; Kipnis, E.; Mebazaa, A.; Misset, B.; Andremont, A.; Ploy, M.-C.; Jacobs, A.; Yarranton, G.; Pearce, T.; Fagon, J.-Y.; Chastre, J. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas Aeruginosa: A randomized, double-Blind, placebo-controlled trial. Crit. Care Med., 2012, 40, 2320-2326.
157. Lu, Q.; Rouby, J.-J.; Laterre, P.-F.; Eggimann, P.; Dugard, A.; Giamarellos-Bourboulis, E.J.; Mercier, E.; Garbino, J.; Luyt, C.-E.; Chastre, J.; Georgescu-Kyburz, V.; Rudolf, M.P.; Gafner, V.; Lazar, H.; Koch, H.; Perez, A.; Krämer, S.D.; Tamm, M. Pharmacokinetics and Safety of Panobacumab: Specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas Aeruginosa O11 pneumonia. J. Antimicrob. Chemother., 2011, 66, 1110-1116.
158. Fernebro, J. Fighting bacterial infections-future treatment options. Drug Resist. Updat., 2011, 14, 125-139.
159. Sulakvelidze, A.; Alavidze, Z.; Morris Jr., J.G. Bacteriophage therapy MINIREVIEW. Antimicrob. Agents Chemother., 2001, 45, 649-659.
160. Summers, W.C. Bacteriophage herapy. Annu. Rev. Microbiol., 2001, 55, 437-451.
161. Housby, J.N.; Mann, N.H. Phage therapy. Drug Discov. Today, 2009, 14, 536-540.
162. Fischetti, V.A.; Nelson, D.; Schuch, R. Reinventing phage therapy: Are the Parts Greater than the Sum? Nat. Biotechnol., 2006, 24, 1508-1511.
163. Hawkins, C.; Harper, D.; Burch, D.; Anggard, E.; Soothill, J. Topical treatment of Pseudomonas Aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol., 2010, 146, 309-313.
164. Marza, J. A. S.; Soothill, J.S.; Boydell, P.; Collyns, T. A. Multiplication of therapeutically administered bacteriophages in Pseudomonas Aeruginosa infected patients. Burns, 2006, 32, 644-646.
165. Soothill, J.S. Bacteriophage prevents destruction of skin grafts by Pseudomonas Aeruginosa. Burns, 1994, 20, 209-211.
166. Khairnar, K.; Raut, M.P.; Chandekar, R.H.; Sanmukh, S.G.; Paunikar, W.N. Novel bacteriophage therapy for controlling metallo-beta-lactamase producing Pseudomonas Aeruginosa infection in catfish. BMC Vet. Res., 2013, 9, 264.
167. Heo, Y.-J.; Lee, Y.-R.; Jung, H.-H.; Lee, J.; Ko, G.; Cho, Y.-H. Antibacterial efficacy of phages against Pseudomonas Aeruginosa infections in mice and drosophila melanogaster. Antimicrob. Agents Chemother., 2009, 53, 2469-2474.
168. Hall, A.R.; De Vos, D.; Friman, V.-P.; Pirnay, J.-P.; Buckling, A. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas Aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol., 2012, 78, 5646-5652.
169. Khawaldeh, A.; Morales, S.; Dillon, B.; Alavidze, Z.; Ginn, A. N.; Thomas, L.; Chapman, S.J.; Dublanchet, A.; Smithyman, A.; Iredell, J.R. Bacteriophage therapy for refractory Pseudomonas Aeruginosa urinary tract infection. J. Med. Microbiol., 2011, 60, 1697-1700.
170. Vieira, A.; Silva, Y.J.; Cunha, A.; Gomes, N.C.M.; Ackermann, H.-W.; Almeida, A. Phage therapy to control multidrug-resistant Pseudomonas Aeruginosa skin infections: In vitro and ex vivo experiments. Eur. J. Clin. Microbiol. Infect. Dis., 2012, 31, 3241-3249.
171. Wright, A.; Hawkins, C.H.; Anggard, E.E.; Harper, D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas Aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol., 2009, 34, 349-357.
172. Alemayehu, D.; Casey, P.G.; Mcauliffe, O. Bacteriophages Pdbl MR299-2 and Pdbl NH-4 can eliminate Pseudomonas Aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio, 2012, 3, e00029-12.
173. Debarbieux, L.; Leduc, D.; Maura, D.; Morello, E.; Criscuolo, A.; Grossi, O.; Balloy, V.; Touqui, L. Bacteriophages can treat and prevent Pseudomonas Aeruginosa lung infections. J. Infect. Dis., 2010, 201, 1096-1104.
174. Fukuda, K.; Ishida, W.; Uchiyama, J.; Rashel, M.; Kato, S.; Morita, T.; Muraoka, A.; Sumi, T.; Matsuzaki, S.; Daibata, M.; Fukushima, A. Pseudomonas Aeruginosa Keratitis in Mice: Effects of topical bacteriophage KPP12 administration. PLoS One, 2012, 7, e47742.
175. Golkar, Z. Experimental phage therapy on multiple drug resistant Pseudomonas Aeruginosa infection in mice. J. Antivir. Antiretrovir., 2013, 05.
176. Kumari, S.; Harjai, K.; Chhibber, S. Bacteriophage treatment of burn wound infection caused by Pseudomonas Aeruginosa PAO in BALB/c mice. Am. J. Biomed. Sci., 2009, 1, 385-394.
177. McVay, C.S.; Velásquez, M.; Fralick, J.A. Phage therapy of Pseudomonas Aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother., 2007, 51, 1934-1938.
178. Morello, E.; Saussereau, E.; Maura, D.; Huerre, M.; Touqui, L.; Debarbieux, L. Pulmonary bacteriophage therapy on Pseudomonas Aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS One, 2011, 6, e16963.
179. Soothill, J.S. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol., 1992, 37, 258-261.
180. Vinodkumar, C.S.; Kalsurmath, S.; Neelagund, Y.F. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas Aeruginosa septicemia in mice introduction. Indian J. Pathol. Microbiol., 2010, 51, 360-366.
181. Wang, J.; Hu, B.; Xu, M.; Yan, Q.; Liu, S.; Zhu, X.; Sun, Z.; Reed, E.; Ding, L.; Gong, J.; Li, Q.Q.; Hu, J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenemresistant Pseudomonas Aeruginosa. Int. J. Mol. Med., 2006, 17, 309-317.
182. Watanabe, R.; Matsumoto, T.; Sano, G.; Ishii, Y.; Tateda, K.; Sumiyama, Y.; Uchiyama, J.; Sakurai, S.; Matsuzaki, S.; Imai, S.; Yamaguchi, K. Efficacy of bacteriophage therapy against gutderived sepsis caused by Pseudomonas Aeruginosa in mice. Antimicrob. Agents Chemother., 2007, 51, 446-452.
183. Yilmaz, C.; Colak, M.; Yilmaz, B.C.; Ersoz, G.; Kutateladze, M.; Gozlugol, M. Bacteriophage therapy in implant-related infections: An experimental study. J. Bone Joint Surg. Am., 2013, 95, 117-125.
184. Rhoads, D.D.; Wolcott, R.D.; Kuskowski, M.A.; Wolcott, B.M.; Ward, L.S.; Sulakvelidze, A. Bacteriophage therapy of venous leg ulcers in humans: Results of a phase I safety trial. J. Wound Care, 2009, 18, 237-238, 240-243.
185. Fukuda, K.; Ishida, W.; Uchiyama, J.; Rashel, M.; Kato, S. ichiro; Morita, T.; Muraoka, A.; Sumi, T.; Matsuzaki, S.; Daibata, M.; Fukushima, A. Pseudomonas Aeruginosa keratitis in mice: Effects of topical bacteriophage KPP12 administration. PLoS One, 2012, 7, e47742.
186. Hagens, S.; Ahsen, U. Von; Gabain, A. Von. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother., 2004, 48, 3817-3822.
187. Essoh, C.; Blouin, Y.; Loukou, G.; Cablanmian, A.; Lathro, S.; Kutter, E.; Thien, H.V.; Vergnaud, G.; Pourcel, C. The susceptibility of Pseudomonas Aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS One, 2013, 8, e60575.
188. Dolmans, D.E.J.G.J.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer, 2003, 3, 380-387.
189. Wainwright, M. Photodynamic antimicrobial chemotherapy (PACT). J. Antimicrob. Chemother., 1998, 42, 13-28.
190. Jacob, H.E.; Hamann, M. Photodynamic alterations of the cell envelope of Proteus Mirabilis and their repair. Photochem. Photobiol., 1975, 22, 237-241.
191. Menezes, S.; Capella, M.A.; Caldas, L.R. Photodynamic action of methylene blue: repair and mutation in Escherichia coli. J. Photochem. Photobiol. B., 1990, 5, 505-517.
192. Drulis-Kawa, Z.; Bednarkiewicz, A.; Bugla, G.; Stręk, W.; Doroszkiewicz, W. Bactericidal effects of the fotolon (chlorin e6) on gram-negative and gram-positive strains isolated from wound infections. Adv. Clin. Exp. Med., 2006, 15, 279-283.
193. Wilson, M.; Mia, N. Effect of environmental factors on the lethal photosensitization of Candida Albicans in vitro. Lasers Med. Sci., 1994, 9, 105-109.
194. Smetana, Z.; Malik, Z.; Orenstein, A.; Mendelson, E.; Ben-Hur, E. Treatment of viral infections with 5-aminolevulinic acid and light.; 1997; Vol. 21, pp. 351-358.
195. Ben-Hur, E.; Oetjen, J.; Horowitz, B. Silicon phthalocyanine Pc 4 and red light causes apoptosis in HIV-infected cells. Photochem. Photobiol., 1997, 65, 456-460.
196. Hamblin, M.R.; Zahra, T.; Contag, C.H.; McManus, A.T.; Hasan, T. Optical monitoring and treatment of potentially lethal wound infections in vivo. J. Infect. Dis., 2003, 187, 1717-1725.
197. Soukos, N.S.; Wilson, M.; Burns, T.; Speight, P.M. Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus Sanguis evaluated in vitro. Lasers Surg. Med., 1996, 18, 253-259.
198. Drulis-Kawa, Z.; Bednarkiewicz, A.; Bugla-Płoskonska, G.; Strek, W.; Doroszkiewicz, W. The susceptibility of anaerobic bacteria isolated from periodontal diseases to photodynamic inactivation with fotolon (chlorin e6). Pol. J. Microbiol., 2005, 54, 305-310.
199. Schastak, S.; Ziganshyna, S.; Gitter, B.; Wiedemann, P.; Claudepierre, T. Efficient photodynamic therapy against grampositive and gram-negative bacteria using THPTS, a cationic photosensitizer excited by infrared wavelength. PLoS One, 2010, 5, e11674.
200. Sharma, M.; Bansal, H.; Gupta, P.K. Virulence of Pseudomonas Aeruginosa cells surviving photodynamic treatment with toluidine blue. Curr. Microbiol., 2005, 50, 277-280.
201. Yamaguchi, T.; Sato, S.; Kawauchi, S.; Terakawa, M.; Shinomiya, N.; Saitoh, D.; Ashida, H.; Obara, M. Efficacy of photodynamic inactivation against Pseudomonas Aeruginosa with pulsed light and CW light excitation. In: SPIE Proceedings; Kessel, D.; Ed. 2006; Vol. 6139, p. 61390V-61390V-7.
202. Hsieh, C.-M.; Huang, Y.-H.; Chen, C.-P.; Hsieh, B.-C.; Tsai, T. 5-Aminolevulinic acid induced photodynamic inactivation on Staphylococcus Aureus and Pseudomonas Aeruginosa. J. Food Drug Anal., 2014, 22, 350-355.
203. Merchat, M.; Bertolini, G.; Giacomini, P.; Villanueva, A.; Jori, G. Meso-substituted cationic porphyrins as efficient photosensitizers of gram-positive and gram-negative bacteria. J. Photochem. Photobiol. B. Biol., 1996, 32, 153-157.
204. Minnock, A.; Vernon, D.I.; Schofield, J.; Griffiths, J.; Parish, J.H.; Brown, S.B. Photoinactivation of bacteria. Use of a cationic watersoluble zinc phthalocyanine to photoinactivate both gram-negative and gram-positive bacteria. J. Photochem. Photobiol. B. Biol., 1996, 32, 159-164.
205. Lee, C.-F.; Lee, C.-J.; Chen, C.-T.; Huang, C.-T. Deltaaminolaevulinic acid mediated photodynamic antimicrobial chemotherapy on Pseudomonas Aeruginosa planktonic and biofilm cultures. J. Photochem. Photobiol. B., 2004, 75, 21-25.
206. Malik, Z.; Ladan, H.; Nitzan, Y. Photodynamic Inactivation of gram-negative bacteria problems and possible solutions. J. Photochem. Photobiol. B., 1992, 14, 262-266.
207. Street, C.N.; Gibbs, A.; Pedigo, L.; Andersen, D.; Loebel, N.G. In vitro Photodynamic eradication of Pseudomonas Aeruginosa in planktonic and biofilm culture. Photochem. Photobiol., 2009, 85, 137-143.
208. Tseng, S.P.; Teng, L.J.; Chen, C.T.; Lo, T.H.; Hung, W.C.; Chen, H.J.; Hsueh, P.R.; Tsai, J.C. Toluidine blue O photodynamic inactivation on multidrug-resistant Pseudomonas Aeruginosa. Lasers Surg. Med., 2009, 41, 391-397.
209. Hashimoto, M.C.E.; Prates, R.; Kato, I.T.; Nunez, S.C.; Courrol, L.C.; Ribeiro, M.S. Antimicrobial photodynamic therapy on drugresistant Pseudomonas Aeruginosa-induced infection. An in vivo Study. Photochem. Photobiol., 2012, 88, 590-595.
210. Hamblin, M.R.; O'Donnell, D.A.; Murthy, N.; Rajagopalan, K.; Michaud, N.; Sherwood, M.E.; Hasan, T. Polycationic photosensitizer conjugates: Effects of chain length and gram classification on the photodynamic inactivation of bacteria. J. Antimicrob. Chemother., 2002, 49, 941-951.
211. Friedberg, J.S.; Tompkins, R.G.; Rakestraw, S.L.; Warren, S.W.; Fischman, A.J.; Yarmush, M.L. Bacteriocidal effects of Sn (IV) chlorin e6-dextran-monoclonal antibody conjugates. Ann. N. Y. Acad. Sci., 1991, 618, 383-393.